This study deals with the pharmacokinetic interaction of selected anti-TB drugs with a natural product (CC-1a) derived from caraway (Carum carvi, L.) seed. CC-1a, chemically standardized butanolic fraction, enhanced the plasma levels of rifampicin, pyrazinamide, and isoniazid in Wistar rat, resulting in increased bioavailability indices (Cmax and AUC) of the drugs. Moreover, a 40% reduced dose regimen of these drugs, which additionally contained CC-1a, was equivalent in terms of Cmax and AUC to a normal dose regimen. A permeation-enhancing property of CC-1a across small intestinal absorptive surface was found to be a contributing factor in its bioavailability enhancing profile.
1 Khatri GR . Controlling tuberculosis in India. New Eng J Med2002; 347: 1420–1425.
2.
2 Yee D Valiquette C Pelletier M Parisien I Rocher I Menzies D . Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med2003; 167: 1472–1477.
3.
3 Gulbay BE Gurkan OU Yildiz OA Onen ZP Erkekol FO Baççıoğlu A . Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respir Med2006; 100: 1834–1842.
4.
4 Tam CM Yew WW Leung CC Chan YC . CDC recommendations against the use of rifampicin and pyrazinamide for treatment of latent tuberculosis infection. MMWR2003; 6: 735–739.
5.
5 Tasduq SA Kaiser P Sharma SC Johri RK . Potentiation of isoniazid-induced liver toxicity by rifampicin in a combination therapy of anti-tubercular drugs (rifampicin, isoniazid and pyrazinamide) in wistar rats: a toxicity profile study. Hepatol Res2007; 37: 845–853.
6.
6 Tasduq SA Kaiser P Koul S Bhat R Johri RK . Biochemical manifestations of anti-tubercular drugs induced hepatotoxicity and the effect of silymarin. Hepatol Res2006; 31: 132–135.
7.
7 Chan K Liu ZQ Jiang ZH Zhou H Wong YF Xu HX . The effects of sinomenine on intestinal absorption of paeoniflorin by the everted rat gut sac model. J Ethnopharmacol2006; 103: 425–432.
8.
8 Lowry OH Rosebrough NJ Farr AL Randall RJ . Protein measurement with Folin phenol reagent. J Biol Chem1951; 193: 265–275.
9.
9 KS Mhaskar E Blatter JF Caius , (). Kiritikar & Basu’s illustrated indian medicinal plants, vol. 5. New Delhi: Satguru Publications; 2000. p. 1670–1672.
10.
10 Tahraoui A El-Hilaly J Israili ZH Lyoussi B . Ethnopharmacological survey of plants used in the traditional treatment of hypertension and diabetes in south-Eastern Morrocco (Errachidia province). J Ethnopharmacol2007; 110: 1105–1117.
11.
11 Khan S Balick MJ . Therapeutic plants of Ayurveda: a review of selected clinical and other studies for 166 species. J Alt Complem Med2001; 7: 405–415.
12.
12 Iacobellis NS Lo Cantore P Capasso F Senatore F . Antibacterial activity of Cuminum cyminum L. and Carum carvi L. essential oils. J Agri Food Chem2005; 53: 57–61.
13.
13 Naderi-Kalali B Allameh A Rasaee MJ Bach HJ Behechti A Doods K . [REMOVED HYPERLINK FIELD] et al. Suppressive effects of caraway (Carum carvi) extracts on 2,3,4,7,8-tetrachlorodibenzo-p- dioxindependent gene expression of cytochrome P450 1A1 in the rat H4IIE cells. Toxicol in Vitro2005; 19: 373–377.
14.
14 Mazaki M Kataoka K Kinouchi T Vinitketkumnuen U Yamada M Nohmi T . Inhibitory effects of caraway (Carum carvi L.) and its component on N-methyl-N’-nitro-N-nitrosoguanidine-induced mutagenicity. J Med Invest2006; 53: 123–133.
15.
15 Kamaleeswari M Deeptha K Sengottuvelan M Nalini N . Effect of dietary caraway (Carum carvi L.) on aberrant crypt foci development, fecal steroids, and intestinal alkaline phosphatase activities in 1,2-dimethylhydrazine-induced colon carcinogenesis. Toxicol Appl Pharmacol2006; 214: 290–296.
16.
16 Kamaleeswari M Nalini N . Dose-response efficacy of caraway (Carum carvi L.) on tissue lipid peroxidation and antioxidant profile in rat colon carcinogenesis. J Pharm Pharmacol2006; 58: 1121–1130.
17.
17 Deeptha K Kamaleeswari M Sengottuvelan M Nalini N . Dose dependent inhibitory effect of dietary caraway on 1,2-dimethylhydrazine-induced colonic aberrant crypt foci and bacterial enzyme activity in rats. Invest New Drugs2006; 24: 479–488.
18.
18 Lemhadri A Hajji L Michel JB Eddouks M . Cholestrol and triglycerides lowering activities of caraway fruits in normal and streptozotocin diabetic rats. J Ethnopharmacol2006; 106: 321–326.
19.
19 Lahlou S Tahraoui A Israili Z Lyoussi B . Diuretic activity of the aqueous extracts of Carum carvi and Tanacetum vulgare in normal rats. J Ethnopharmacol2007; 110: 458–463.
20.
20 Eddouks M Lemhadri A Michel JB . Caraway and caper: potential anti-hyperglycaemic plants in diabetic rats. J Ethnopharmacol2004; 94: 143–148.
21.
21 Satyanarayana S Sushruta K Sarma GS Srinivas N Subba Raju GV . Antioxidant activity of the aqueous extracts of spicy food additives- evaluation and comparison with ascorbic acid in in-vitro systems. J Herbal Pharmacother2004; 4: 1–10.
22.
22 Khayyal MT el-Ghazaly MA Kenaway SA Seif-el-Nasr M Mahran LG Kafafi YA . Antiulcerogenic effect of some gastrointestinally acting plant extracts and their combination. Arzneimittelforschung2001; 51: 545–553.
23.
23 Mhady GB Pendland SL Stoia A Hamill FA Fabricant D Dietz BM . In vitro susceptibility of Heliobactor pylori to botanical extracts used traditionally for the treatment of gastrointestinal disorders. Phytother Res2005; 19: 988–991.
24.
24 Zhou S Lim LY Chowbay B . Herbal modulation of P-glycoprotein. Drug Metab Rev2004; 36: 1–48.
25.
25 Venkataramanan R Komoroski B Strom S . In vitro and in vivo assessment of herb drug interactions. Life Sci2006; 78: 2105–2115.
26.
26 Pal D Mitra AK . MDR- and CYP3A4-mediated drug –herbal interactions. Life Sci2006; 78: 2131–2145.
27.
27 Petri WA . Drugs used in the chemotherapy of tuberculosis, Mycobacterium avium complex disease, and leprosy. In: JG Hardman LE Limberd , (eds). Goodman and Gilman’s the pharmacological basis of theapeutics, 10th ed.New York: McGraw Hill Medical Publishing Division; 2001. p. 1273–1294.
28.
28 Williams RL . Bioequivalence and therapeutic equivalence. In: PG Welling FLS Tse SV Dighe , (eds). Pharmaceutical bioequivalence.New York: Marcel Dekker Inc; 1991. p. 1–15.
29.
29 Brown JR Collett JH Attwood D Ley RW Sims EE . Influence of monocaprin on the permeablity of a diacidic drug BTA-243 across Caco-2 cell monolayers and everted gut sacs. Int J Pharmaceutics2002; 245: 133–142.
30.
30 Bennet LZ Cummins CL . The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev2001; 50: S3–S11.
31.
31 Williamson EM . Synergy and other interactions in phytomedicines. Phytomedicine2001; 8: 401–412.
32.
32 Spinella M . The importance of pharmacological synergy in psychoactive herbal medicines. Alt Med Rev2002; 7: 130–142.
